Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Phase II CONTROL trial.

被引：13

作者：

Barcenas, Carlos Hernando

Hurvitz, Sara A.

Di Palma, Jack A.

Bose, Ron

Chan, Arlene

Chien, Amy Jo

Farrell, Cindy

Hunt, Daniel

McCulloch, Leanne

Kupic, Amy

Tripathy, Debu

Rugo, Hope S.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Univ S Alabama, Coll Med, Mobile, AL USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Breast Canc Res Ctr WA, Perth, WA, Australia

[6] Curtin Univ, Perth, WA, Australia

[7] Univ Calif San Francisco, San Francisco, CA 94143 USA

[8] Puma Biotechnol Inc, Los Angeles, CA USA

[9] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

548

引用

页数：2